Table 3.

Risk for intrinsic breast cancer subtypes associated with statin use

Study populationStatin use, ≥2 yStatin use, neverOR* (95% CI)
Luminal A
    Controls8,990 (17.5)42,355 (82.5)Reference
    Cases948 (18.2)4,265 (81.8)1.09 (1.00 - 1.18)
Luminal B
    Controls1,841 (14.4)10,910 (85.6)Reference
    Cases178 (13.8)1,110 (86.2)0.99 (0.82 -1.19)
HER2+/ER−
    Controls676 (12.9)4,574 (87.1)Reference
    Cases71 (13.0)474 (87.0)1.05 (0.78-1.42)
Triple negative
    Controls1,118 (12.3)7,984 (87.7)Reference
    Cases111 (12.1)810 (87.9)0.93 (0.74 - 1.18)
  • *Odds ratios based on conditional logistic regression among cases classified by intrinsic subtype and respective matched controls, adjusted for oral contraceptive and hormone therapy use.